The G protein-coupled receptor GPRC6A (GPCR, Class C, group 6, subtype A) has been proposed to be a sensor for basic L-amino acids that are hypothesized to translate ingestive behaviour to endocrine information. However, the contribution of the GPRC6A receptor to L-amino acid-induced glucagon-like peptide 1 (GLP-1) secretion is unclear. Therefore, to discover whether the GPRC6A receptor is indispensible for amino acid-induced secretion of GLP-1, we treated, with oral gavage, GPRC6A knock-out (KO) and wild-type (WT) littermate mice with GPRC6A ligands (L-arginine and L-ornithine) and assessed GLP-1 levels in circulation. We found that oral administration of both L-arginine and L-ornithine significantly increased total plasma GLP-1 levels to a similar level in GPRC6A KO and WT mice 15 minutes after gavage (both amino acids) and accumulated up to 60 minutes after gavage (L-arginine). Conversely, GLP-1 secretion at the 30-and 60-minute time points in the KO mice was attenuated and did not reach statistical significance. In summary, these data confirm that L-arginine is a potent GLP-1 secretagogue and show that the main effect occurs independently of GPRC6A. In addition, this is the first study to show that also L-ornithine powerfully elicits GLP-1 release in vivo.
| INTRODUCTION
Pharmacological targeting of the glucagon-like peptide 1 receptor (GLP-1R) is a widely employed strategy to treat obesity and type 2 diabetes. 1 Further, mounting evidence supports the notion that the metabolic benefits of bariatric surgery are coupled with amplification in meal-induced GLP-1 secretion. 2 Therefore, nutritional strategies aiming to boost endogenous GLP-1 release are being explored currently as safe therapeutic alternatives to surgical and pharmacological interventions. 3 It was discovered recently that the basic amino acid Larginine is a potent GLP-1 secretagogue and the benefits of L-arginine in aiding glycaemic control depend on functional GLP-1R signalling. 4 A decade ago, we cloned an amino acid-sensing G proteincoupled receptor, termed GPRC6A (GPCR, Class C, group 6, subtype A), and subsequently hypothesized that basic amino acids such as Larginine and L-ornithine may elicit metabolic benefits, including GLP-1 secretion in a GPRC6A-dependent manner. [5] [6] [7] In addition, it has been proposed that testosterone and osteocalcin exert metabolic effects via activation of GPRC6A. 7 In 2012, Oya and colleagues reported that L-ornithine stimulates GLP-1 secretion in vitro in
GLUTag cells via stimulation of GPRC6A. 8 However, in the same study Oya et al. could hardly detect GPRC6A in FACS-sorted intestinal endocrine cells, putting into question the extrapolation of results to the in vivo situation. 8 Very recently Murphy et al. revealed that ablation of the GPRC6A gene does not compromise arginineinduced benefits on glucose tolerance. 9 Likewise, L-arginine-mediated PYY secretion from primary mouse colonic epithelium was not compromised by GPRC6A ablation, whereas L-arginine-mediated GLP-1 release was attenuated, 9 leaving the potential physiological role of GPRC6A in basic amino acid-mediated incretin hormone secretion unresolved.
The aim of the present study was to examine whether the GPRC6A receptor is necessary for L-arginine-and L-ornithineinduced GLP-1 secretion in vivo.
# Shared co-first authorship.
GPRC6A KO mice with a disruption of exon VI from the GPRC6A gene were generated as previously described. 10 The statistical level of significance is determined at P < .05. Oral administration of 1 g/kg L-arginine also led to significantly increased total plasma GLP-1 levels after 15 minutes in both GPRC6A full locus KO and WT mice ( Figure 2A ) (WT mice, P < .01, 12.6 AE 1.7 pM at 0 minutes, 26.7 AE 2.5 pM at 15 minutes, n = 9;
| RESULTS
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GPRC6A KO mice, P < .01, 8.8 AE 1.3 pM at 0 minutes, 29.1 AE 3.8 pM at 15 minutes, n = 5). In the WT mice, the elevated GLP-1 secretion was retained at the 30-minute and 60-minute time points, whereas an attenuated GLP secretion was observed for the full locus GPRC6A KO mice (WT mice, P < .01, 27.9 AE 3.1 pM at 30 minutes; P < .05, 23.7 AE 8.2 pM at 60 minutes, n = 9; GPRC6A KO mice, P > .05, 18.2 AE 2.9 pM at 30 minutes; P > .05, 
| DISCUSSION
There is a rapidly growing interest in understanding how dietary components can act as signalling molecules to affect human biology beyond their energetic value. 11 L-arginine supplementation has been shown to have widespread metabolic benefits in mice, rats, pigs and humans. [12] [13] [14] [15] In addition, research dating back more than 50 years has contributed to positioning L-arginine as a major endocrine regulator, and today we know that arginine exhibits powerful control over the humoral factors governing energy metabolism, including insulin, glucagon, growth hormone and GLP-1. 4, [16] [17] [18] Despite this knowledge, the molecular underpinnings of the endocrine and metabolic benefits of arginine are incompletely understood.
We have recently shown that L-arginine-mediated insulin release does not require GPRC6A 19 and Murphy et al. have demonstrated that L-arginine reduces food intake in a GPRC6A-independent manner. 9 In agreement with these results, we have observed identical glucose levels after oral glucose gavage in WT and GPRC6A KO mice under normal physiological conditions. 19 But, given the clear meta- 
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